Brepocitinib

Brepocitinib (PF-06700841) is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC50s of 17 nM and 23 nM, respectively. Brepocitinib also inhibits JAK2 and JAK3 with IC50s of 77 nM and 6.49 μM, respectively[1].

Product Specifications

CAS Number

[1883299-62-4]

Product Name Alternative

PF-06700841

UNSPSC

12352005

Hazard Statement

H303, H315, H319, H335

Target

JAK

Type

Reference compound

Related Pathways

Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/PF-06700841.html

Purity

99.97

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C([C@H]1C(F)(F)C1)N2C3CN(C4=NC(NC5=CN(C)N=C5)=NC=C4)CC2CC3

Molecular Formula

C18H21F2N7O

Molecular Weight

389.40

Precautions

H303, H315, H319, H335

References & Citations

[1]Fensome A, et al. Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S) -2,2-Difluorocyclopropyl) ((1 R,5 S) -3- (2- ((1-methyl-1 H-pyrazol-4-yl) amino) pyrimidin-4-yl) -3,8-diazabicyclo[3.2.1]octan-8-yl) methanone (PF-06700841) . J Med Chem. 2018 Oct 11;61 (19) :8597-8612.